DKC1 and breast carcinoma: Three inhibitors were developed based on the interaction between DKC1 and TERC to inhibit telomerase activity in breast cancer cell lines, which may aid in development of pseudouridine synthase inhibitors for treatment of cancer (Armando et al., 2018).